Kornimate/medical-research-clean huggingface dataset:
cardiac arrhythmias and the perception of symptoms

Conditions: Cardiovascular Diseases; Heart Diseases; Arrhythmia

Summary: to investigate the differential diagnosis and longitudinal course of medical outpatients complaining of palpitations. also, to further examine the process of cardiac perception, the psychological factors which influence it, and the accurate awareness of cardiac arrhythmias.

design narrative: one hundred seventy-five consecutive patients referred for continuous ambulatory electrocardiographic (holter) monitoring because of palpitations were studied. the investigators assessed cardiac symptoms, psychiatric diagnosis, life stress, beliefs about heart disease, somatization, and bodily absorption and amplification. cardiac awareness, cardiac symptoms and cardiac activity were assessed during holter monitoring and exercise tolerance testing (ett). the referring physicians completed instruments rating their diagnostic impressions and clinical interventions. the patients' clinical course was then followed over the ensuing 12 months with telephone interviews and in-person assessments. these data permitted description and distinguished three subgroups of palpitation patients: those with panic disorder, in whom the symptom resulted from sympathetic nervous system arousal; those who were somatizing after a life event caused them to suspect that they had heart disease, in whom the palpitation resulted from a cognitive misattribution of benign bodily sensation; and those with clinically significant arrhythmias, whose symptoms resulted from a major cardiac irregularity. these findings were used to develop a clinical algorithm to aid in the differential diagnosis of palpitations and in identifying the patients most appropriate for holter monitoring. the patients' longitudinal course was followed to determine the predictors of continued somatization and chronicity, and to study their medical care by examining the referring physicians' diagnostic impressions and interventions. by comparing cardiac symptoms with concurrent cardiac activity during holter monitoring and ett, the investigators hoped to develop measures of cardiac awareness. they would then be able to describe inter-individual differences in cardiac awareness, examine several psychological factors which amplify or modulate awareness, and investigate the relationship between somatization and accuracy of symptom reporting. it was hoped that the findings would ultimately lead to improved cognitive and educational techniques to reassure and palliate palpitation patients, and to the early identification of patients who were unlikely to obtain symptomatic relief from antiarrhythmic therapy. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
fibromyalgia, exercise adherence and barriers

Conditions: Fibromyalgia

Summary: we aimed to investigate adherence to exercise and perceived barriers to exercise in patients with fibromyalgia who were advised to exercise.


Eligibility criteria:
inclusion criteria: * being diagnosed with fibromyalgia according to acr 2016 criteria * female * to be informed about the benefits of exercise, the importance of exercise compliance and to be shown the exercise program in practice and to be given a printed form exclusion criteria: * having a systemic or mental disease that may prevent exercise
sub-macular injection of ranibizumab as a new surgical treatment for refractory diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: the best treatment strategy for refractory dme is not known, options include switching between anti-vegf agents, corticosteroids, and vitrectomy. in this study, authors describe a new surgical technique for the treatment of refractory non tractional dme. the technique consists of vitrectomy with ilm peeling with subretinal injection of ranibizumab.

purpose: in this study, authors describe a new surgical technique for the treatment of refractory dme. the technique consists of vitrectomy with ilm peeling with subretinal injection of ranibizumab. methods: this is a prospective interventional non-comparative study including patients with refractory dme. included patients were subjected to the new surgical technique of pars plana vitrectomy with sub-retinal injection of ranibizumab.

Eligibility criteria:
inclusion criteria: * refractory diffuse non tractional dme. * central retinal thickness (crt) should exceed 350 µm despite undergoing multiple anti-vegf therapy. * decimal best corrected visual acuity (bcva) must be ≥0.01 and ≤0.5. exclusion criteria: * previous vitrectomy, recent cataract surgery less than 6 months, * evident rpe atrophy, proliferative diabetic retinopathy, massive foveal hard exudation, foveal traction on oct, * glaucoma and one eyed patients.
effect of tooth angulation, alveolar and basal bone anatomical characteristics on soft and hard tissue alterations around immediate implants with customized healing abutment

Conditions: Immediate Implant; Esthetic Zone; Customized Healing Abutment; Tissue Collapse; Tissue Dimensional Changes

Summary: the goal of this clinical trial is to investigate the effect of different anatomical variations in terms of root angulation, alveolar bone and basal bone morphology on soft and hard tissue alterations in patients with non-restorable teeth in the inter-canine region undergoing immediate implantation. the main question it aims to answer are: * will the amount of collapse be greater when the root is proclined or outside the bone housing? * will no additional intervention be needed with immediate implants in the esthetic zone if we have better anatomy that will help hinder the collapse? participants will receive immediate dental implants with customized healing abutments


Eligibility criteria:
inclusion criteria: patient-related criteria: * adults at or above the age of 21. * non-restorable maxillary inter-canine tooth requiring extraction and needed an implant placing therapy. * the failing tooth will have adjacent and opposing natural teeth. * sufficient mesial-distal and interocclusal space for placement of the implant and definitive restoration. * able to tolerate surgical periodontal procedures. * good oral hygiene. * compliance with the maintenance program. * provide informed consent. * accepts the one-year follow-up period. teeth related criteria: * intact thick biotype gingival tissue with at least 2mm band of keratinized tissue. * intact socket wall before the extraction, buccal bone thickness ≤1mm assessed by cbct. * sufficient apical bone to place an immediate implant with minimum primary stability of 30ncm. exclusion criteria: * patients diagnosed with periodontal diseases. * current or previous smokers. * pregnant and lactating females. * patients with medical conditions that would compromise the surgical procedures; uncontrolled diabetes mellitus, taking iv bis-phosphonates for treatment of osteoporosis. * patients with active infection related at the site of implant/bone graft placement. * patients with parafunctional habits
repeatability of blood glucose responses to resistance exercise in type 1 diabetes

Conditions: Type 1 Diabetes

Summary: this study proposes to examine the impact of time of day (morning versus afternoon) on the variability of blood glucose responses to high resistance exercise in a single group of patients with type 1 diabetes. participants will be asked to wear a continuous glucose monitor during the 3 weeks of testing. during the six exercise sessions (three in the morning while fasted and three in the afternoon), participants will complete the same resistance exercise protocol.

pre-test measures: interested participants will be invited to the physical activity and diabetes laboratory on the main campus of the university of alberta. they will be asked questions related to their physical activity levels and medication, and blood pressure will be measured to assess their eligibility. where participants are eligible, anthropometric characteristics will be measured using standard protocols, as will blood pressure. a blood sample will be drawn for assessment of hba1c. participants will be introduced to the weight lifting equipment and the proper lifting techniques associated with each exercise prior to performing a standardized test to determine the maximum weight they can safely lift eight times while maintaining proper form (8 repetition maximum - 8rm). testing sessions: participants will be asked to arrive at the lab either between 7 and 8 am in a fasting state, or between 4 pm and 5 pm. the three morning and three afternoon testing sessions will have identical exercise protocols. participants will be asked to perform three sets of eight repetitions of seven different exercises (bench press leg press, shoulder press, leg curl, lat pulldown, abdominal crunches, seated row) at their pre-determined 8rm. participants will be asked to match their food and insulin intake as closely as possible on testing days to avoid having these as confounders. a continuous glucose monitor (cgm) sensor will be subcutaneously inserted by one of the investigators (trained by a group from the cgm manufacturer) into the anterior abdominal area of the participant in the morning of the day prior to the first testing session. cgm will store glucose data every 5 minutes for up to 7 days. during this time, participants will be asked to wear an accelerometer to allow for the objective assessment of background physical activity and sleep quality. along with this device, they will fill out an activity and sleep log to improve the analysis of the data.

Eligibility criteria:
inclusion criteria: * type 1 diabetes diagnosed for at least 1 year * aged 18 to 55 years exclusion criteria: * hba1c \> 9.9% * frequent and unpredictable hypoglycemia * change in insulin management strategy within two months of study * using closed-loop insulin delivery * injuries that would contraindicate resistance exercise * blood pressure \> 140/95 * severe peripheral neuropathy * a history of cardiovascular disease * severe proliferative retinopathy
digihaler in chronic obstructive pulmonary disease (copd)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this is a multi-center 3-month study to determine the variation in proair digihaler metrics \[peak inspiratory flow (pif), inhalation volume, number of inhalation events\] amongst copd patients in the ambulatory setting.

the albuterol sulfate electronic multidose dry powder inhaler (albuterol emdpi) digital system (ds) (proair® digihaler®) is the first and only food and drug administration (fda) approved inhaler rescue medication with a built-in sensor to detect and record inhaler use. the inhaler device measures pif and the app groups pif into categories that can help to highlight potential patient inhaler technique errors. this study will deploy this product in copd patients to establish foundational data on digihaler metrics in a copd population at greater risk for copd exacerbations. adult subjects with copd recruited from two sites \[university of north carolina (unc) and wake forest\] will participate in a longitudinal study to collect data regarding the normal variation in digihaler metrics (pif, inhalation volume, number of inhalations), a daily self-assessment asking "how are you feeling?" with responses provided on a likert scale as well as responses to a digihaler metric algorithm-triggered digital automated questionnaire (daq) in a stable copd population with history of an aecopd, to assess correlations of digihaler metrics to daily self-assessment and daq responses, correlations of self-reported to actual short acting beta agonist (saba) use and symptoms, and the changes in inhaler parameters and saba use around incidental aecopd.

Eligibility criteria:
inclusion criteria: * age \>40 years old * history of cigarette smoking \>=10 pack-years * established copd defined as physician diagnosis along with spirometry confirmation \[post-bronchodilator (bd) forced expiratory volume in 1 second (fev1)/forced vital capacity (fvc)\<0.70\] within the last two years and an fev1 ≤80% predicted * regular albuterol use (defined as at least one puff weekly for each of the last four weeks) * currently non-hospitalized * medical records confirmed history of two moderate aecopd (defined as use of antibiotic or steroids to treat clinical event consistent with aecopd) or one severe aecopd (defined as emergency department/hospital visit) in prior 12 months * access to smart phone, tablet or computer and internet * willingness to switch current rescue inhaler/device to proair digihaler exclusion criteria: * allergy or inability/contraindication to use albuterol sulfate * any condition that, in the opinion of the site investigator, would compromise the subject's ability to participate in the study

Keywords: bronchial diseases respiratory tract diseases lung diseases, obstructive lung diseases albuterol bronchodilator agents respiratory system agents
perineal massage and warm compresses - rct for reduce perineal trauma during labor

Conditions: Perineal Tear Resulting From Childbirth

Summary: the aim of this study is to evaluate the effect of a combined perineal massage and warm compresses intervention on the perineum integrity during second stage of labor.

a single-centre, prospective, randomized controlled trial was conducted. eligibility and informed consent to participate were checked once the woman was in established labor. eligible participants were randomized at the second stage of labor. the trial intervention took place during the second stage of the spontaneous vaginal birth. participants were randomized to one of the two groups, perineal massage and warm compresses on second stage of labor or control group (hands-on).

Eligibility criteria:
inclusion criteria: * women with 18 years or older * between 37 and 41 weeks of pregnancy * expected spontaneous vaginal birth * fetus in the cephalic presentation * able to provide informed written consent exclusion criteria: * multiple pregnancy * meconial amniotic fluid * fetal distress * suspicion of fetal growth restriction * gestational hypertensive disorders

Keywords: perineum
safety of cultured allogeneic adult umbilical cord derived mesenchymal stem cell intravenous infusion for ms

Conditions: Multiple Sclerosis

Summary: this trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of multiple sclerosis

multiple sclerosis (ms) can be a devastating disease. there is evidence that mesenchymal stem cell treatment is safe and efficacious for the treatment of ms. patients with ms will receive a single intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells. the dose for the infusion will be 100 million cells. patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy. for patients with more severe disease requiring chemotherapeutic drugs such as methotrexate, an autologous t cell vaccine will be utilized created from the patient's own t cells obtained by apheresis

Eligibility criteria:
inclusion criteria: * diagnosis of multiple sclerosis * understanding and willingness to sign a written informed consent document exclusion criteria: * active infection * active cancer * chronic multisystem organ failure * pregnancy * clinically significant abnormalities on pre-treatment laboratory evaluation * medical condition that would (based on the opinion of the investigator) compromise patient's safety. * continued drug abuse * pre-menopausal women not using contraception * previous organ transplant * hypersensitivity to sulfur

Keywords: multiple sclerosis ms stem cell treatment
effects of local insulin on wound angiogenesis

Conditions: Angiogenesis

Summary: randomized, split plot, double-blind, placebo controlled trial. half of the wounds surface was applied daily with insulin and the other half with saline solution as placebo. biopsy specimens of the two sides were obtained on days 0 and 14. number of blood vessels will be evaluated as main outcome.

randomized, split plot, double-blind, placebo controlled trial. non-diabetic patients with full-thickness wounds will be treated in the following manner: in half of the surface insulin will be applied in a daily basis, on the other half, saline solution will be used as placebo. biopsy specimens of both sides will be obtained on days 0 and 14. number of blood vessels will be evaluated as main outcome.

Eligibility criteria:
inclusion criteria: * nondiabetic patients with full-thickness acute wounds exclusion criteria: * diabetic patients

Keywords: blood vessel fibroplasia wound healing insulin
acute exposure of simulated hypoxia on pulmonary artery pressure and right heart function (echo)

Conditions: Pulmonary Hypertension

Summary: randomized crossover trial in patients with pulmonary hypertension (pah, cteph) to assess the acute response to simulated altitude (fio2:15.1, equivalent to 2500m above sea level) on pulmonary artery pressure and right heart function (echo).

low altitude baseline measurements will be performed in zurich (460m asl) including echocardiography, right heart catheterization, (six-minute walk test) 6mwt, pulmonary function test, clinical assessment and blood gas analysis. randomly assigned to the order of testing, the participants will be tested under simulated altitude (fio2: 15.1% with the "amc altitrainer") and shamed altitude with the same device. several times within the exposure, the pulmonary artery pressure and the right heart function will be assessed by echo.

Eligibility criteria:
inclusion criteria: * informed consent * ph diagnosed according to internation guidelines: mean pulmonary artery pressure (mpap) ≥ 25 mmhg along with a (pulmonary artery wedge pressure) pawp ≤15 mmhg during right heart catheterization at the time of initial diagnosis * ph class 1 (pah) or 4 (cteph) * stable condition, on the same medication for \> 4 weeks * patient live permanently at an altitude \< 1000m asl. exclusion criteria: * resting partial oxygen pressure (pao2) ≤7.3 kilopascal (kpa) corresponding to the requirement of long-term oxygen therapy \> 16hour daily (nocturnal oxygen therapy alone is allowed) * severe daytime hypercapnia (pco2 \> 6.5 kpa) * susceptibility to high altitude related diseases (ams, high-altitude pulmonary edema (hape), etc.) based on previous experienced discomfort at altitudes. * exposure to an altitude \>1500m for ≥3 nights during the last 4 weeks before the study participation * residence \> 1000m above sea level * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic problems with walking disability * women who are pregnant or breast feeding

Keywords: simulated altitude pulmonary artery pressure echocardiography right heart function
t1 mapping in fabry disease

Conditions: Fabry Disease

Summary: fabry disease (omim-301500, fd) is a lysosomal storage disease with x-linked inheritance secondary to mutations in the α-galactosidase a gene (gla), which cause absence or decreased activity of the lysosomal hydrolase a-galactosidase a (a-gal a). the accumulation of globotriaosylceramide (gb3) leads to multiple organs dysfunction, especially in three key organs: kidney, heart and cerebrovascular system. progressive nephropathy is one of the main features of fabry disease and is marked by an insidious development. the investigators are facing different current challenges about treatment initiation in non-classic phenotype patients, optimal dose after treatment initiation, and treatments monitoring in fabry nephropathy. that is even more important that the enzyme replacement therapy is expensive and a lifelong commitment. functional magnetic resonance imaging (mri) is now able to provide t1 mapping sequence. in fabry disease, t1 mapping is currently used to assess the degree of myocardial involvement. the mri for assessement of fabry cardiomyopathy is now recommended by the 2022 national diagnostic and care protocol (pnds) in france. however there is no data about t1 mapping values in kidney in fabry's disease the main objective is to describe renal performance through multi-parametric mri in fabry nephropathy and the primary outcome will be the quantification of renal t1 in fabry patients.


Eligibility criteria:
inclusion criteria: * patient with confirmed fabry disease or control patients: patients undergoing renal functional exploration for a reason other than fabry disease, amyloidosis, hemochromatosis * adult patient * patient informed of the study and agree to participate * patient affiliated to a social security or beneficiaries of a similar scheme exclusion criteria: * weight \> 130 kg * kidney transplant, * polycystic kidney disease, * pregnant, parturient or breastfeeding * contraindications to mri * subject participating in another research including an exclusion period still in progress at inclusion * persons deprived of their liberty by a judicial or administrative decision, * adults subject to a legal protection measure (safeguard measure, guardianship, curators)

Keywords: fabry disease t1 mapping functional mri fabry nephropathy
risk of reactivation of occult hepatitis b in cancer patients during immunotherapy.

Conditions: Occult Hepatitis B Infection in Cancer Patients

Summary: the goal of this observational study is to evalue the cumulative proportion of patients with obi who do not develop hbsag seroreversion and/or an increase of serum hbv dna by at least 1 log above the lower limit of detection of the assay in a patient who had previously undetectable hbsag and hbv dna in serum during the study.


Eligibility criteria:
inclusion criteria: * life-expectancy (as estimated by treating physician) ≥ 6 months; * patients hbsag negative * patients hbcab positive with or without hbv-dna detectable * patients with cancer undergoing immunotherapy with or without chemotherapy exclusion criteria: * patients who did not give informed consent * patients under prophylaxis for hbv * patients vaccinated for hepatitis b * patients with hbsag positivity * patients with hiv positivity * patients with current history of alcohol (more than 5 alcohol unit daily) and drug use * patients with other cause of liver disease with known etiology (autoimmune liver disorder and storage liver disease) * patients with current active hepatitis c virus (hcv-positive) * patients with hepatocellular carcinoma (hcc)